Skip Navigation


Cardiovascular Research Advance Access first published online on November 27, 2008
This version [Corrected Proof] published online on December 15, 2008
Cardiovascular Research, doi:10.1093/cvr/cvn327
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow All Versions of this Article:
81/4/703    most recent
cvn327v2
cvn327v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Palomer, X.
Right arrow Articles by Vázquez-Carrera, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Palomer, X.
Right arrow Articles by Vázquez-Carrera, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2008. For permissions please email: journals.permissions@oxfordjournals.org.

TNF-{alpha} reduces PGC-1{alpha} expression through NF-{kappa}B and p38 MAPK leading to increased glucose oxidation in a human cardiac cell model

Xavier Palomer1, David Álvarez-Guardia1, Ricardo Rodríguez-Calvo1, Teresa Coll1, Juan C. Laguna1, Mercy M. Davidson2, Tung O. Chan3, Arthur M. Feldman3 and Manuel Vázquez-Carrera1,*

1 Pharmacology Unit, Department of Pharmacology and Therapeutic Chemistry, IBUB (Institut de Biomedicina de la Universitat de Barcelona) and CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM)-Instituto de Salud Carlos III, Faculty of Pharmacy, University of Barcelona, Building A, 643 Diagonal Ave, E-08028 Barcelona, Spain
2 Department of Neurology, Columbia University, Russ Berrie Medical Pavilion, Room 301, 1150 St Nicholas Avenue, New York, NY 10032, USA
3 Center for Translational Medicine, Department of Medicine, Thomas Jefferson University, RM 813 College Building, 1025 Walnut St., Philadelphia, PA 19107, USA

* Corresponding author. Tel: +34 93 4024531; fax: +34 93 4035982.E-mail address: mvazquezcarrera{at}ub.edu

Aims: Inflammatory responses in the heart that are driven by sustained increases in cytokines have been associated with several pathological processes, including cardiac hypertrophy and heart failure. Emerging data suggest a link between cardiomyopathy and myocardial metabolism dysregulation. To further elucidate the relationship between a pro-inflammatory profile and cardiac metabolism dysregulation, a human cell line of cardiac origin, AC16, was treated with tumour necrosis factor-{alpha} (TNF-{alpha}).

Methods and results: Exposure of AC16 cells to TNF-{alpha} inhibited the expression of peroxisome proliferator-activated receptor coactivator 1{alpha} (PGC-1{alpha}), an upstream regulator of lipid and glucose oxidative metabolism. Studies performed with cardiac-specific transgenic mice (Mus musculus) overexpressing TNF-{alpha}, which have been well characterized as a model of cytokine-induced cardiomyopathy, also displayed reduced PGC-1{alpha} expression in the heart compared with that of control mice. The mechanism by which TNF-{alpha} reduced PGC-1{alpha} expression in vitro appeared to be largely mediated via both p38 mitogen-activated protein kinase and nuclear factor-{kappa}B pathways. PGC-1{alpha} downregulation resulted in an increase in glucose oxidation rate, which involved a reduction in pyruvate dehydrogenase kinase 4 expression and depended on the DNA-binding activity of both peroxisome proliferator-activated receptor β/{delta} and estrogen-related receptor {alpha} transcription factors.

Conclusion: These results point to PGC-1{alpha} downregulation as a potential contributor to cardiac dysfunction and heart failure in metabolic disorders with an inflammatory background.

KEYWORDS Peroxisome proliferator-activated receptor {gamma} coactivator 1{alpha}; NF-{kappa}B; TNF-{alpha}

Time for primary review: 39 days


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.